YL064 activates proteasomal-dependent degradation of c-Myc and synergistically enhances the anti-tumor activity of ABT-199 in diffuse large B cell lymphoma-Reference-Cited by-同舟云学术

YL064 activates proteasomal-dependent degradation of c-Myc and synergistically enhances the anti-tumor activity of ABT-199 in diffuse large B cell lymphoma

Published:2020-07-06 Issue:1 Volume:5 Page:
ISSN:2059-3635
Container-title:Signal Transduction and Targeted Therapy
language:en
Short-container-title:Sig Transduct Target Ther

Author:

Shan Huizhuang,Cao Yang,Xiao Xinhua,Liu Meng,Wu Yunzhao,Zhu Qi,Xu Hanzhang,Lei Hu^ORCID,Yao Zhujun^ORCID,Wu Yingli^ORCID

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics

Link

http://www.nature.com/articles/s41392-020-00236-1.pdf

Reference5 articles.

1. Karube, K. & Campo, E. MYC alterations in diffuse large B-cell lymphomas. Semin Hematol.52, 97–106 (2015).

2. Ott, G., Rosenwald, A. & Campo, E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood122, 3884–3891 (2013).

3. Esteve-Arenys, A. et al. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Oncogene37, 1830–1844 (2018).

4. Chen, G.-Q., Xu, Y., Shen, S.-M. & Zhang, J. Phenotype and target-based chemical biology investigations in cancers. Natl Sci. Rev.6, 1111–1127 (2019).

5. Wang, Y. et al. YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells. Cell Death Discov.4, 44 (2018).

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Novel SIRT1/2 Inhibitors with Effective Cytotoxicity against Human Leukemia Cells;Journal of Chemical Information and Modeling;2023-07-24

2. Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV‑2 papain-like protease;Acta Biochimica et Biophysica Sinica;2022-07-01

3. Expanding the armory for treating lymphoma: Targeting redox cellular status through thioredoxin reductase inhibition;Pharmacological Research;2022-03

4. Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents;Infectious Complications in Biologic and Targeted Therapies;2022

5. Ribosome 18S m6A methyltransferase METTL5 promotes pancreatic cancer progression by modulating c‑Myc translation;International Journal of Oncology;2021-12-28